Showing 2031-2040 of 4063 results for "".
- China Gives Green Light to Allergan’s Xen Registration for the Surgical Management of Refractory Glaucomahttps://modernod.com/news/china-gives-green-light-to-allergans-xen-registration-for-the-surgical-management-of-refractory-glaucoma/2477514/Allergan announced China’s National Medical Products Administration (NMPA) approved the registration of Allergan’s Xen Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. Xen is th
- Allergan to Present New Data on Investigational Medicines at AAOhttps://modernod.com/news/allergan-to-present-new-data-on-investigational-medicines-at-aao/2479768/Allergan will present new data at the annual meeting of the American College of Ophthalmology (AAO) to be held in Chicago. The Retina Subspecialty Day (October 26-27) will feature two late-breaker presentations on the
- ImprimisRx to Feature New Formulation and Poster Presentation on MKO Melt at AAO Meeting in Chicagohttps://modernod.com/news/imprimisrx-to-feature-new-formulation-and-poster-presentation-on-mko-melt-at-aao-meeting-in-chicago/2479781/ImprimisRx announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) annual meeting to be held at the McCormick Place Convention Center in Chicago, October 26-30. At the conference, attendees will have the opportunity to meet with ImprimisRx representatives
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Oxurion's THR-149 vs Aflibercept for Treatment of DMEhttps://modernod.com/news/first-patient-dosed-in-part-b-of-phase-2-kalahari-study-evaluating-oxurions-thr-149-vs-aflibercept-for-treatment-of-dme/2480445/
- AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at American Academy of Ophthalmology 2021 Annual Meetinghttps://modernod.com/news/agtc-presents-data-from-ongoing-phase-12-trial-of-agtc-501-at-upcoming-american-academy-of-ophthalmology-2021-annual-meeting/2480436/
- Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)https://modernod.com/news/oyster-point-pharma-submits-a-phase-2-clinical-trial-protocol-to-evaluate-oc-01-nasal-spray-for-neurotrophic-keratitis-nk/2478616/Oyster Point Pharma announced it has submitted to the FDA a protocol to initiate a clinical study in adult patients with neurotrophic keratitis (NK). The submission was made to Oyster Point’s investigational new drug (IND) for OC-01 (varenicline) nasal spray in dry eye disea
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- Nova Eye to Feature Several Presentations and Posters Related to iTrack Canaloplasty at 2024 ESCRS Annual Congresshttps://modernod.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/Nova Eye Medical has announced that the company’s proprietary canaloplasty technology platform (iTrack and iTrack Advance) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons